117 related articles for article (PubMed ID: 15559606)
1. [Development of binding antibodies to interferon-beta during treatment of multiple sclerosis with different types of interferon-beta].
Bartosik-Psujek H; Mitosek-Szewczyk K; Belniak E; Stelmasiak Z
Pol Merkur Lekarski; 2004 Jul; 17(97):28-32. PubMed ID: 15559606
[TBL] [Abstract][Full Text] [Related]
2. [The assessment of development of binding antibodies to interferon beta during interferon beta 1a treatment of multiple sclerosis].
Bartosik-Psujek H; Belniak E; Mitosek-Szewczyk K; Rejdak K; Dobosz B; Stelmasiak Z
Neurol Neurochir Pol; 2003; 37(4):799-809. PubMed ID: 14746240
[TBL] [Abstract][Full Text] [Related]
3. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
4. Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b.
Speciale L; Saresella M; Caputo D; Ruzzante S; Mancuso R; Calvo MG; Guerini FR; Ferrante P
J Neurovirol; 2000 May; 6 Suppl 2():S57-61. PubMed ID: 10871787
[TBL] [Abstract][Full Text] [Related]
5. An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.
Garg N; Weinstock-Guttman B; Bhasi K; Locke J; Ramanathan M
Mult Scler; 2007 Aug; 13(7):895-9. PubMed ID: 17468449
[TBL] [Abstract][Full Text] [Related]
6. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
Río J; Nos C; Tintoré M; Borrás C; Galán I; Comabella M; Montalban X
Ann Neurol; 2002 Oct; 52(4):400-6. PubMed ID: 12325067
[TBL] [Abstract][Full Text] [Related]
7. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
[TBL] [Abstract][Full Text] [Related]
8. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
9. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.
Patti F; Pappalardo A; Florio C; Politi G; Fiorilla T; Reggio E; Reggio A
Acta Neurol Scand; 2006 Apr; 113(4):241-7. PubMed ID: 16542163
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
11. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
12. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
[TBL] [Abstract][Full Text] [Related]
13. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
Boz C; Oger J; Gibbs E; Grossberg SE;
Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
[TBL] [Abstract][Full Text] [Related]
14. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
Río J; Nos C; Tintoré M; Téllez N; Galán I; Pelayo R; Comabella M; Montalban X
Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
[TBL] [Abstract][Full Text] [Related]
15. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
[TBL] [Abstract][Full Text] [Related]
16. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
17. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
[TBL] [Abstract][Full Text] [Related]
18. Long time interval between multiple sclerosis onset and occurrence of primary Sjögren's syndrome in a woman treated with interferon-beta.
De Santi L; Costantini MC; Annunziata P
Acta Neurol Scand; 2005 Sep; 112(3):194-6. PubMed ID: 16097964
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
20. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
